Fennec Pharmaceuticals Stock Today
| FENC Stock | USD 8.80 0.26 3.04% |
PerformanceSolid
| Odds Of DistressLow
|
Fennec Pharmaceuticals is trading at 8.80 as of the 6th of July 2025, a 3.04 percent increase since the beginning of the trading day. The stock's open price was 8.54. Fennec Pharmaceuticals has less than a 15 % chance of experiencing some financial distress in the next two years of operation and had a solid performance during the last 90 days. The performance scores are derived for the period starting the 7th of April 2025 and ending today, the 6th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of June 2001 | Category Healthcare | Classification Health Care |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. Fennec Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 27.62 M outstanding shares of which 1.36 M shares are currently shorted by private and institutional investors with about 12.42 trading days to cover. More on Fennec Pharmaceuticals
Moving together with Fennec Stock
Moving against Fennec Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Fennec Stock Highlights
| CEO, Director | Rostislav Raykov | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsFennec Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Fennec Pharmaceuticals' financial leverage. It provides some insight into what part of Fennec Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Fennec Pharmaceuticals (FENC) is traded on NASDAQ Exchange in USA. It is located in 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709 and employs 32 people. Fennec Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 247.39 M. Fennec Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.62 M outstanding shares of which 1.36 M shares are currently shorted by private and institutional investors with about 12.42 trading days to cover.
Fennec Pharmaceuticals currently holds about 14.91 M in cash with 26.98 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57.
Check Fennec Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationFennec Pharmaceuticals holds a total of 27.62 Million outstanding shares. Over half of Fennec Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Fennec Ownership Details
Fennec Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Lion Point Capital, Lp | 2025-03-31 | 195.7 K | |
| Gendell Jeffrey L | 2025-03-31 | 195.2 K | |
| Northern Trust Corp | 2025-03-31 | 138.4 K | |
| Dg Capital Management, Llc | 2025-03-31 | 84.2 K | |
| Charles Schwab Investment Management Inc | 2025-03-31 | 61.1 K | |
| Bank Of New York Mellon Corp | 2025-03-31 | 53.5 K | |
| Hartford Financial Management Inc. | 2025-03-31 | 49.8 K | |
| Goldman Sachs Group Inc | 2025-03-31 | 43.2 K | |
| Bnp Paribas Arbitrage, Sa | 2025-03-31 | 41 K | |
| Southpoint Capital Advisors Lp | 2025-03-31 | 4.1 M | |
| Sonic Gp Llc | 2024-12-31 | 2.4 M |
Fennec Pharmaceuticals Historical Income Statement
Fennec Stock Against Markets
Fennec Pharmaceuticals Corporate Management
| Mark Meier | VP Commercial | Profile | |
| Christiana MBA | Chief Officer | Profile | |
| Mark Gowland | Controller | Profile | |
| Terry Evans | Chief Officer | Profile | |
| Robert Andrade | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.53) | Revenue Per Share 1.127 | Quarterly Revenue Growth (0.66) | Return On Assets (0.13) | Return On Equity |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.